Search bioRxiv⌕ Search

bioRxiv · 10.1101/2024.01.11.575256

A dual histone code specifies the binding of heterochromatin protein Rhino to a subset of piRNA source loci

Abstract

Animal germ cells deploy a specialized small RNA-based silencing system, called the PIWI-interacting RNA (piRNA) pathway, to prevent unwanted expression of transposable elements and maintain genome integrity. In Drosophila germ cells, the majority of piRNA populations originate from dual-strand piRNA clusters, genomic regions highly enriched in transposable element (TE) fragments, via an elaborate protein machinery centred on the heterochromatin protein 1 homolog, Rhino. Although Rhino binds to peptides carrying trimethylated H3K9 in vitro, it is not fully understood why in vivo only a fraction of H3K9me3-decorated heterochromatin is occupied by Rhino. Recent work revealed that Rhino is recruited to a subset of piRNA clusters by the zinc finger protein Kipferl. Here we identify a Kipferl-independent mode of Rhino targeting that, in addition to the previously established role of H3K9me3, also depends on the histone H3 lysine 27 methyltransferase Enhancer of Zeste. At Kipferl-independent sites, we find that Rhino, through its chromodomain, specifically binds to loci marked by both H3K9me3 and H3K27me3. Although the exact mechanism of how Rhino binding is influenced by dual histone modifications remains unclear from a structural and biochemical perspective, our work suggests that combinatorial modifications can play a crucial role in influencing the specificity of chromatin-binding protein interactions. These findings provide an enhanced understanding of the multifaceted mechanisms by which Rhino targets piRNA source loci highlighting the sophisticated epigenetic landscape governing TE silencing in Drosophila germ cells. Our work further reveals a role for dual histone modifications defining the binding specificity of a key chromatin protein.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Akkouche, A., Kneuss, E., Bornelöv, S., Renaud, Y., Eastwood, E. L., van Lopik, J., Gueguen, N., Jiang, M., Creixell, P., Maupetit-Mehouas, S., Nicholson, B. C., Brasset, E., Hannon, G. J.. 2024-01-11. A dual histone code specifies the binding of heterochromatin protein Rhino to a subset of piRNA source loci. https://doi.org/10.1101/2024.01.11.575256

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

AGPAT2 Inflammatory Metabolic Reprogramming Mediates Immune Checkpoint Inhibitor-associated Myocarditis via LPAR5-pyroptosis Axis

Objectives: Immune checkpoint inhibitors (ICIs), especially programmed cell death protein-1 (PD1) inhibitors, are effective onco-therapeutic agents. However, ICI-associated myocarditis (ICIAM) greatly limits their clinical utility. Imbalance between 1-acylglycerol-3-phosphate O-acyltransferases (AGPAT2) and lysophosphatidic acid (LPA) induced by inflammatory metabolic reprogramming (IMRP) might cause cardiovascular injury. This study aims to explore the link between AGPAT2 pathway and ICIAM as well as identifies diagnosis and treatment targets of ICIAM. Methods: ICIAM model was established by injecting anti-PD1 (PD1) in wild-type (WT) and AGPAT2 heterozygous knockout (AGPAT2+/-) mice. The pathogenic and regulating mechanisms of AGPAT2-LPA and its downstream signaling were examined in vitro and in vivo. A tumor-patient cohort was enrolled to observe the association between serum LPA and risk of ICIAM. Results: In the PD1-induced ICIAM model, myocardial IMRP occurred due to upstream immunity disorder, leading to downstream AGPAT2 degradation via lysosomal pathway and subsequent LPA accumulation. Knockout of AGPAT2 gene also promoted LPA accumulation. The accumulated LPA, by binding to its dominant receptor subtype 5 (LPAR5), triggered pyroptotic myocardial damage and resultant ICIAM. LPAR5 knockdown with siRNA or inhibition with TCLPA5-4 played the most significant rescue effect on myocardial pyroptosis, while stimulating LPAR5 with overdose LPA significantly increased myocardial pyroptosis. In ICI-treated patients, elevated serum LPA was associated with increased risk of ICIAM. Conclusions: IMRP-triggered dysfunction of AGPAT2-LPA-LPAR5-pyroptosis axis is involved in pathogenesis of ICIAM. Several elements in this axis may be the promising targets in diagnosis (LPA as a biomarker) and treatment (LPA or LPAR5 as therapeutics) of ICIAM.

molecular biology↗

Accessibility-guided targeting of NRF2-responsive long noncoding RNA NMRAL2P alters a distinct gene expression program and reduces non-small cell lung cancer proliferation

Aberrant activation of the antioxidant transcription factor NRF2 promotes non-small cell lung cancer (NSCLC) survival and therapy resistance, but downstream effectors beyond redox regulation remain incompletely defined. Transcriptome profiling of lung and NSCLC cells identified the pseudogene-derived long noncoding RNA LOC344887/NMRAL2P as consistently associated with NRF2 activity. The NMRAL2P locus produces three predominant, nuclear-localized isoforms whose expression depends on NRF2 across normal lung, lung adenocarcinoma, and lung squamous carcinoma cells. In-cell SHAPE-MaP identified accessible regions within NMRAL2P transcripts, guiding antisense gapmer design. NMRAL2P depletion inhibited NSCLC cell proliferation and increased sensitivity to cisplatin. Transcriptome analysis revealed that NMRAL2P depletion altered a restricted gene expression program involving cell adhesion and MAPK signaling, with responses distinct from those observed following NRF2 depletion. Core NRF2 antioxidant target genes were largely unaffected by NMRAL2P depletion. These findings support a model in which NRF2 induces NMRAL2P to sustain a distinct gene expression program that contributes to NSCLC proliferation and survival. NMRAL2P represents an RNA effector downstream of NRF2 that links oncogenic NRF2 activity to cellular functions beyond canonical antioxidant responses, providing a potential point of intervention in NRF2-active lung cancers and motivating further investigation of the mechanisms connecting this nuclear RNA to signaling pathways.

molecular biology↗

Single-AAV-mediated cardiomyocyte-specific adenine base editing ameliorates cardiac hypertrophy in vivo

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder, frequently accompanied by cardiac hypercontractility, diastolic dysfunction, heart failure and sudden cardiac death. The disease is predominantly caused by pathogenic variants in genes encoding sarcomeric proteins and current therapeutic strategies largely focus on symptom management. Adeno-associated virus-based (AAV) delivery of base editing tools has emerged as an alternative strategy that acts directly on the genetic cause of disease. However, canonical SpCas9-based editors are too large to package into a single-AAV vector which mandates dual-AAV approaches that require higher overall vector doses with elevated toxicity risk and increased manufacturing costs. Here, we report the development and application of a single vector approach for cardiomyocyte-specific adenine base editing to correct a Dutch founder mutation in MYBPC3 (c.2827C>T, p.Arg943Ter) that causes HCM. We systematically compared compact base editors in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and selected the most efficient configuration, which reversed disease-associated hypercontractility in engineered human myocardium (EHM). To fit the editor/guide construct in a single-AAV vector, we screened a library of rationally designed small chimeric promoters and identified 6C2 to effectively drive expression in hiPSC-CMs and cardiac tissue of both mice and non-human primates (NHP) with exceptional specificity. Delivered in a single next-generation cardiotropic AAV capsid, we achieved therapeutic correction in an HCM mouse model at doses 20-fold below published dual-AAV cardiomyopathy base editing approaches. These results establish cardiomyocyte-specific, single vector-mediated base editing as a viable therapeutic strategy for inherited cardiomyopathies.

molecular biology↗